Solid corporate governance forms the foundation of our business
To establish a reliable relationship with shareholders, employees, and other stakeholders, a robust corporate governance structure is key. In addition, it is also crucial to ensure Moberg Pharma is managed responsibly, and in compliance with applicable laws, regulations, and best practices governing the company's operations.
In a constantly changing world, with a focus both internally and externally on good corporate governance, Moberg Pharma is working to continuously improve its corporate governance model. Good corporate governance leads to better quality in the decisions made by those who manage the business.
Moberg Pharma’s focus on product quality, the environment and sustainability, responsible leadership and ethical decision-making also contributes to a sustainable business and long-term value creation.
Following market approval in 2023, Moberg Pharma is now in a transformation phase from a late-stage pharmaceutical development company to launching the competencies needed to be a company with pharmaceuticals on the market. This means among other things more focus on quality systems and sourcing. Corporate governance work creates the conditions for Moberg Pharma to ensure that it meets the expectations it faces, including how sustainability issues are integrated throughout the business.
One focus area in 2023 was to work with continuity risks in the company’s operations, including securing a long-term supply of terbinafine. This work continues in 2024. All in all, the corporate governance year 2023 resulted in further improvements that even better equip Moberg Pharma for the future. Corporate Governance Report 2023